RareWays is a research directory. It helps you understand the science. It is not medical advice. Always discuss your care options with your healthcare team.
Coverage: 2020-01-01 onwards, with up to 300 results per query from PubMed and Europe PMC and separate limits on other sources. This is a selected index, not a complete literature search.
Updates are delayed or unverified. Check original sources for the latest information.
Your saved research and appointment questionsView recorded trial and retraction changes
Atypical Haemolytic Uraemic Syndrome: Research Summary
Printed from RareWays (rareways.org)
For general awareness only. Not medical advice. Discuss all care options with your healthcare team.
5 Most Recent Research Articles
- 1.
The Proteasome Paradox: Navigating Carfilzomib-Induced Atypical HUS in Multiple Myeloma
, International Journal of Drug Delivery Technology (9 October 2026)
https://doi.org/10.25258/ijddt.16.58s.158
- 2.
Fatal haemophagocytic lymphohistiocytosis and atypical haemolytic uraemic syndrome following coronavirus disease 2019 infection.
Khong Jennifer et al., BMJ case reports (7 October 2026)
https://pubmed.ncbi.nlm.nih.gov/42843919/
- 3.
Atypical hemolytic uremic syndrome patients’ perspective in the era of complement inhibitors.
Eva Jenny et al., Kidney International Reports (1 October 2026)
https://doi.org/10.1016/j.ekir.2026.107140
- 4.
Free factor XIII-B in atypical hemolytic uremic syndrome: a remission signal
Arijit Biswas et al., Research and Practice in Thrombosis and Haemostasis (1 October 2026)
https://doi.org/10.1016/j.rpth.2026.107006
- 5.
Comparison between effectiveness and safety of plasma therapy and complement inhibitors for the treatment of atypical hemolytic uremic syndrome: a systematic review and meta-analysis of real-world data.
Le Thy Phuong Anh et al., Pediatric nephrology (Berlin, Germany) (1 October 2026)
https://pubmed.ncbi.nlm.nih.gov/41838094/
Clinical Trials : Australian Sites
Ask your doctor whether you or your child may be eligible for any of these trials. Each has its ID and full eligibility criteria at the link shown.
- 1.
Study of ALXN1210 in Complement Inhibitor Treatment-Naïve Adult and Adolescent Participants With Atypical Hemolytic Uremic Syndrome (aHUS)
NCT02949128 · Completed · Phase 3 · Alexion Pharmaceuticals, Inc.
https://clinicaltrials.gov/study/NCT02949128
Source: RareWays research directory. Data from PubMed, Europe PMC, OpenAlex, ClinicalTrials.gov.
Always verify information with your healthcare team before making any decisions about your care.
Atypical Haemolytic Uraemic Syndrome
Atypical haemolytic uraemic syndrome is a rare condition in which an overactive complement system, part of the immune system, damages small blood vessels. This can destroy red blood cells, lower platelets and injure the kidneys, sometimes leading to kidney failure. It is often linked to inherited or acquired complement problems. Treatment includes complement-blocking medicines and supportive care.
This overview is general information, not an individual medical assessment. Research is selected automatically and may include mismatches. How we select and explain research.
Most Recent Research
Thrombotic microangiopathy (TMA) encompasses a triad of anaemia, low platelet count and organ damage.Haemolytic uremic syndrome is a thrombotic microangiopathy characterised by thrombocytopenia, hemolysis and renal dysfunction.The pathophysiology of hemolytic uremic syndrome has been extensively explored, however, the mechanisms of carfilzomib induced atypical haemolytic uremic syndrome remains incompletely elucidated.Here we present a unique case of carfilzomib-induced atypical haemolytic uremic syndrome in a female with multiple myeloma on carfilzomib therapy.This atypical haemolytic uremic syndrome was treated with cessation of the offending drug, initiation of Eculizumab and PLEX.Renal function improved within days of carfilzomib cessation.
Common Questions
What is Atypical Haemolytic Uraemic Syndrome?
Atypical haemolytic uraemic syndrome is a rare condition in which an overactive complement system, part of the immune system, damages small blood vessels. This can destroy red blood cells, lower platelets and injure the kidneys, sometimes leading to kidney failure. It is often linked to inherited or acquired complement problems. Treatment includes complement-blocking medicines and supportive care.
How many clinical trials are available for Atypical Haemolytic Uraemic Syndrome?
RareWays currently indexes 22 clinical trials for Atypical Haemolytic Uraemic Syndrome, of which 4 are actively recruiting. These counts cover indexed trials across countries, not just your country. An Australian site does not necessarily mean that site is recruiting. Check locations, eligibility and current availability with the study team.
Where does the research data for Atypical Haemolytic Uraemic Syndrome come from?
RareWays aggregates research from PubMed, Europe PMC, OpenAlex, and ClinicalTrials.gov. Data is refreshed automatically every day. All articles and trials link directly to their original sources.
Get research updates
Monthly email when new findings are published for Atypical Haemolytic Uraemic Syndrome.
Your email and selected disease are stored for these updates. Unsubscribe any time. Privacy and deletion.
This information is for general awareness only.
For guidance specific to your situation, please speak with your healthcare team.